Results 191 to 200 of about 23,046 (254)

Therapeutic Tools for Vulvovaginal Candidiasis: Current and Emerging Antifungal Agents. [PDF]

J Fungi (Basel)
Quindós G, De-la-Pinta I, Marcos-Arias C, Jauregizar N, Sevillano E, Madariaga L, Eraso E.   +6 more
europepmc   +1 more source

Antifungal susceptibility profiles of candidemia isolates on the east coast of Peninsular Malaysia and reliability of Etest compared to Sensititre YeastOne. [PDF]

Microbiol Spectr
Abdullah SNS, Tzar MN, Othman SN.
europepmc   +1 more source

Uncommon aortic prosthesis vegetation due to <i>Histoplasma capsulatum</i>: clinical and laboratory aspects. [PDF]

Med Mycol Case Rep
de Lima-Neto RG, Jucá MB, de Albuquerque Gomes TC, Roberta Soares Rodrigues K, Inácio CP, Neves RP.   +5 more
europepmc   +1 more source

Olorofim in combination with azole antifungals: results from the Phase 2 salvage therapy study. [PDF]

J Antimicrob Chemother
Maertens J, Chen SCA, Thompson GR, Donovan F, Dane A, Birch M, Pinder C, Bennett J, Ravenna V, Marin Fernandez O, Ross G, Zinzi D, Rex JH, Phase 2b Olorofim Salvage Therapy Study Group .   +13 more
europepmc   +1 more source

Successful Control of Refractory <i>Coccidioides</i> Meningitis With MAT2203. [PDF]

Open Forum Infect Dis
Mehta SR, Johns S, Matkovits T, Ferguson J, Fierer J.   +4 more
europepmc   +1 more source

High prevalence of cross-class azole resistance among Candida isolates from oropharyngeal candidiasis in HIV-positive cohort in southeast Nigeria. [PDF]

BMC Infect Dis
Eze II, Ossai EN, Oke B, Ene CB, Ekwealor CC, Oyeka CA.   +5 more
europepmc   +1 more source

Natural product based approaches to overcome <i>Candida glabrata</i> and emerging AMR threats. [PDF]

Front Antibiot
Sahu BK, Patra SK, Sahu MC, Panda SK.
europepmc   +1 more source